ANALYSIS: Will Sun-Ranbaxy Pairing Trigger More M&As In India?

The Indian pharmaceutical market is seeing a decisive shift. Starting now, Sun and Ranbaxy as a combined organization will dislodge Abbott from its top position held for over five years. Will companies respond with more merger deals or stay with incremental organic growth?

MUMBAI – As Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. embark on a new journey as a single company, the merger’s impact on the Indian pharmaceutical market is set to be wide-ranging, with a deeply expanded reach and influence on prescriptions.

A few experts suggest top tier companies may already be looking at taking on the combined marketing might of Sun-Ranbaxy and considering serious M&A proposals in areas that could bridge...

More from Focus On Asia

More from Scrip